While taste changes during treatment with GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists are generally benign and self-limiting, certain situations warrant medical evaluation to rule out complications or alternative diagnoses
Sensitivity to specific sweeteners, such as stevia What This Could Mean for Food and Beverage Innovation Taken together, the research suggests a potential shift in sensory expectations among some consumers using GLP-1 therapies
GLP-1 drugs mimic this hormone
Low blood sugar may occur if these weight management medications are taken in addition to glucose-lowering drugs that can cause hypoglycemia (eg, insulin or a sulfonylurea)
Any changes in appearance are due to fat loss around the pubic area and improvements in blood flow or hormonal health, not actual tissue growth
Dosing: Start 2.5 mg injected SQ once weekly in the abdomen, thigh, or upper arm